Journals / Optimal Tıp Derg. / 2002 / Cilt: 15 - Sayı: 2

Beta talesemi major'lü çocuklarda plazma protein C, protein S, antitrombin-III ve fibrinojen düzeyleri

Plasma protein C, protein S, antithrombin-III and fibronogen levels of children with beta thalesemia major

Pages
35–40
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Consequently, oral anticoagulant and mini dose heparin can be applied in the treatment of venous thrombosis and Protein C and Antithrombin-III replacement treatment can be applied additionally.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Protein C and Protein S and Antithrombin-HI, are natural anticoagulant, most of the important element that maintain equilirium between coagulation ve anticoagulation.
📊
Key Findings & Data:Protein C, Protein S and Antithrombin 111 levels were analysed by coagulometer of plasma from 33 Thalessemia major and matched 30 health children.
💡
Conclusion & Impact:Consequently, oral anticoagulant and mini dose heparin can be applied in the treatment of venous thrombosis and Protein C and Antithrombin-III replacement treatment can be applied additionally.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:beta-Talasemi · Protein C · Protein S

Abstract

Protein C and Protein S and Antithrombin-HI, are natural anticoagulant, most of the important element that maintain equilirium between coagulation ve anticoagulation. The risk ofthromboemboly of thalasemic patients is much more greater than normal population. The purpose of this study was to investigate some of hemostasis and thrombosis parameters of children with thalassemia major and introducing and understanding of reasons for tromboembolic damage. Protein C, Protein S and Antithrombin 111 levels were analysed by coagulometer of plasma from 33 Thalessemia major and matched 30 health children. Protein C activity levels of patients and the control group were measured as %50.54±20.13, and %94.66±32.62 respectively. The differences between patients and the control group was statistically significant. (p<0.001). Protein S activity levels of patients and the control group was 53.16+27.46 %, and 74.46+20.19 % respectively.(p<0,001) Antithrombin-III levels of patients was 94.51+20.02 % and the level of control group was 119.33±11.70 %.(p<0.001) Fibrinogen levels of patients and the control group were 239.06+61.48 mg/dL, 269.93±72.50 mg/dL respectively.(p>0.05) In patient group a positive relation was found between Protein S and Antithrombin-III levels.(p<0,05) In control group a negative relation was found between Protein C-Protein S (p<0,05) and a negative relation found between Protein C-flbrinogen.(p<0.05) These data indicate that naturel anticoagulants are decrease in beta-thalassemia. Consequently, oral anticoagulant and mini dose heparin can be applied in the treatment of venous thrombosis and Protein C and Antithrombin-III replacement treatment can be applied additionally.

Özet

Protein C, Protein S ve Antitrombin III, koagulasyon ve antikoagulasyon arasındaki dengenin sürdürülmesinde görev alan önemli doğal antikoagulanlardır. Talasemik hastalardaki tromboemboli riski, normal populasyondan daha fazladır. Bu çalışmanın amacı, Talesemi majorlü çocuklarda hemostaz ve tromboz parametrelerinin bir kısmını araştırmak ve tromboembolik hasarın sebeplerim anlamaktır. Protein C, Protein S ve Antitrombin IH düzeyleri, Beta talesemi majorlü 43 hastadan ve 40 sağlıklı çocuktan alınan plazma örneklerinde koagulometre cihazında çalışıldı. Hasta ve kontrol grubunun Protein C aktivite düzeyleri sırası ile % 50,5420,13 ve % 94,66±32,62 olarak ölçüldü. Hasta ve kontrol grubu arasındaki farkılılıklar istatistiksel olarak anlamlıydı (p 0,05). Hasta grubunda Protein S ve Antitrombin III düzeyleri arasında pozitif bir ilişki gözlendi (p<0,05). Kontrol grubunda, protein C-Protein S arasında (p<0,05) ve Protein C ile fibrinojen arasında negatif bir ilişki bulundu (p<0,05). Elde edilen bu veriler Beta talesemide doğal anticoagulanların azaldığını belirtir.

🔖

Cite This Article

KAYA, M. N., YOKUŞ, B., AYDINOL, B. G. (2002). Beta talesemi major'lü çocuklarda plazma protein C, protein S, antitrombin-III ve fibrinojen düzeyleri. Optimal Tıp Derg., Cilt: 15 - Sayı: 2, 35–40. https://ajindex.com/articles/288617

References (17)

  1. Weatherall DJ, Clegg JB, Wood WG: The hemoglobinopaties In: Sciver CR, Beaudet Al, Valle D (ed): The metabolic basis of inherited disease. McGraw Hill Information Series Co. 1989, pp 2281-2339
  2. Lee GR, Bithell TC, Foerster J, Athens JW, Lukens J.N: Wintrobe's Clinical Hematology (9th ed) Philadelphia, Lea-Febiger. 1993, pp 89-93
  3. Nathan DG, Oski FA: Hematology of infancy and childhood, (4th ed) Philadephia, W.B. Saunders Company. 1993,ppl27-132
  4. Gabuti V, Piga A, Sacchetti L, Sadri A, et al: Quality and life expectancy in thalasemic patients with complications. Prog Clin Biol Res. 1989; 309: 35-41
  5. Montalembert M, Girot R, Revillon Y. et al: Partial Splenektomy in homozygous b-thalassaemia Arch-Dis-Child. 1990; 65 (3): 304-307
  6. Thomas ED, Buckner CD, Sanders JE:' Bone marrow Transplantation for thalassemia. Lancet 1990; 31: 227-229
  7. De Stafano V, Finazzi G, Manucci M: Inheridet thrombophilia, pathogenesis, clinical syndroms and management. Blood. 1996; 87: 3531-32
  8. Lane DA, Manucci PM, Bauer, KA: Inheridet thrombophilia: part-I Thromb Haemost. 1996; 76: 651-58 9. Rodgers GM: Thrombosis and antithrombotic theraphy. In: Wintrobe's Clinical Heamatology (10th Ed). Williams and Wilkins Comp.1998, pp 1781-1818
  9. Clous L, Comp P, et al.: The Regulation of Hemostasis: The protein C system, The N Engl J Med. 1986; 314 (20): 1298-1304
  10. Griffin J, Evatt B, Zimmerman T, Klesi A, Widemann G: Deficiency of Protein C in Congenital Trombotik Disease. J. Clin Invest. 1981; 68: 1370-1373
  11. Makris M, Rosendaal FR, Preston FE: i Familial thrombophilia: Genetic rise factors and managment. J Int. Med. 1997; 242: 9-15
  12. Kolodziej M, Comp PC: Hypercoagulable states due to naturel anticoagulant deficiencies. Curr. Op. Hematol. 1993; 2:301-303 14. Bauer KA.: The Hypercoagulable state in: Williams Hematology 5th edition, McGraw-Inc. 1995,pp 1531-1549
  13. Rosandaal FR: Venoz thrombosis: a multicausal disease. Lancet 1999; 353:1167-71
  14. Eldor A, Durst RE, Hy-am G, Gıllıs S, Rachmilemtz.EA, Abromov A, Macloue J, Godefray YC, Raucord: A chronic hypercaogulable state in patients with Beta thalasemia majör is already present in childhood. British J. Of Haem. 1999; 107:739-746
  15. Esmon CT: Protein C prog. Hemost. Thromb. 1984; 25: 25-29
  16. Bauer GA, Rosanberg RD: The pathophisiology of the prethrombotic state jn human, inside gained from studies using markers of hemostatic system activation. Blood. 1987; 70: 343-47
  17. Giardano P, Del Vecchio